1. Brown GC, Magargal LE, Schachat A, Shah H. Neovascular glaucoma. Etiologic considerations. Ophthalmology. 1984; 91:315–20.
2. Loffler KU. Neovascular glaucoma: aetiology, pathogenesis and treatment. Ophthalmologe. 2006; 103:1057–63.
3. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006; 37:144–6.
Article
4. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006; 142:1054–6.
Article
5. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001; 108:1767–79.
6. Lee KW. Management of Neovascular glaucomas. J Korean Ophthalmol Soc. 1988; 29:596–603.
7. Magargal LE, Brown GC, Augsburger JJ, Donoso LA. Efficacy of panretinal photocoagulation in preventing neovascular glaucoma following ischemic central retinal vein obstruction. Ophthalmology. 1982; 89:780–4.
Article
8. Duker JS, Brown GC. The efficacy of panretinal photocoagulation for neovascularization of the iris after central retinal artery obstruction. Ophthalmology. 1989; 96:92–5.
Article
9. Brooks AM, Gillies WE. The development and management of neovascular glaucoma. Aust N Z J Ophthalmol. 1990; 18:179–85.
10. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age‐ related macular degeneration. Ophthalmology. 2006; 113:363–72.
11. Silva Paula J, Jorge R, Alves Costa R, et al. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Opthalmol Scand. 2006; 84:556–7.
Article
12. Zweng HC, Little LH. Argon laser photocoagulation. St. Louis: The CV. Mosby;1977. p. 263–5.